Body Systems

Alzheimer's Disease13 Results found

Studies recruiting participants:

validation of the Dépistage Cognitif de Québec: A new Cognitive Screening Tool

The purpose of this study is to validate the English version of a new cognitive screening tool, the "Dépistage Cognitif de Québec" (DCQ).  The DCQ is a valid instrument that can be administered in less than 45 minutes and unlike other screening tools for dementia, it can provide more detailed inf

Recruiting
Principal Investigator 
Ging-Yuek Robin Hsiung
Body Locations and Systems 
Alzheimer's Disease, Dementia
Area 
Vancouver
Age 
50 and above

Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)

The purpose of this project is to conduct a proof of concept study in patients with probable Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure,

Recruiting
Principal Investigator 
Ging-Yuek Robin Hsiung
Body Locations and Systems 
Alzheimer's Disease, High Blood Pressure
Area 
Vancouver
Age 
50 and above

Microbiome in Alzheimer's Disease

Recent evidence suggests a connection between the gut and the brain, and that certain conditions in the gut might be associated with neurological diseases.  Research suggests that people with Alzheimer's Disease differ from healthy controls with respect to the bacteria (microbiome) present in the

Recruiting
Principal Investigator 
Ging-Yuek Robin Hsiung
Body Locations and Systems 
Alzheimer's Disease
Area 
Vancouver
Age 
50-85

Closed for recruitment:

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at…

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of gantenerumab and solanezumab in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves cognitive outcomes and disease-relat

Closed for Recruitment
Principal Investigator 
Ging-Yuek Robin Hsiung
Body Locations and Systems 
Alzheimer's Disease, Neurologic Diseases, Dementia
Area 
Vancouver
Age 
18-80

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2.

Closed for Recruitment
Principal Investigator 
Haakon Nygaard
Body Locations and Systems 
Alzheimer's Disease
Area 
Vancouver
Age 
55-85

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD.

Closed for Recruitment
Principal Investigator 
Ging-Yuek Robin Hsiung
Body Locations and Systems 
Alzheimer's Disease
Area 
Vancouver
Age 
50-85